Modulating the Tumor Microenvironment: Small-Molecule Strategies in Combination Regimens

Small-molecule inhibitors (SMIs) have become indispensable tools in precision oncology, offering the ability to selectively target intracellular signaling pathways, metabolic processes, and epigenetic regulators that sustain malignant growth. However, the complexity of tumor ecosystems—shaped by diverse immune, stromal, metabolic, and structural components of the tumor microenvironment (TME)—often limits the durability of SMI monotherapies. This chapter provides a comprehensive overview of the evolving role of SMIs within combination regimens designed to simultaneously disrupt tumor-intrinsic pathways and reprogram the tumor-supportive microenvironment. We first outline the molecular basis and functional diversity of small-molecule agents, followed by a detailed examination of TME cellular and noncellular components that influence tumor progression and therapeutic resistance. We then explore the mechanistic rationale, preclinical evidence, and expanding clinical landscape of SMI-based combination approaches—including kinase inhibitors paired with immune checkpoint blockade, metabolic modulators combined with immunotherapy, and epigenetic agents integrated into multimodal regimens. Special emphasis is placed on experimental findings demonstrating the dual tumor-targeting and immune-reprogramming potential of SMI combinations, such as the synergistic galunisertib–doxorubicin strategy in aggressive lymphoma. Together, these insights highlight a major paradigm shift: from single-agent precision targeting to integrated, multi-axis therapeutic strategies. As clinical trials continue to broaden and refine these combinations, SMIs are poised to remain central components of next-generation regimens aimed at achieving durable responses and overcoming TME-driven resistance mechanisms.